No Data
No Data
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH): has repurchased 2.07% of the shares.
On September 2, Gleonhui announced that as of September 2, 2024, Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) has repurchased a total of 1.21066 million shares through centralized bidding trading, accounting for 2.07% of the total share capital. The highest purchase price is 79.70 yuan/share, the lowest purchase price is 69.70 yuan/share, and the total amount paid is 92.0759 million yuan (excluding stamp duty, trading commission, and other transaction fees).
Jiangsu Shuoshi Biotechnology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Shuoshi Biotechnology Co., Ltd.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) released its performance for the first half of the year, with a net income of 29.2405 million yuan, turning losses into profits year-on-year.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) released its semi-annual report for 2024, during which the company achieved revenue of 1...
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): The monkeypox detection products are exported to some African countries.
On August 21, Bioperfectus Technologies (688399.SH) stated on the investor interactive platform that the company's monkey pox detection products are exported to some African countries. Currently, the revenue from overseas market business accounts for a small proportion of the company's overall business income. The company will closely monitor the overseas market situation.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) has given up its priority subscription rights for the capital increase of its associated company YUANSONG BIOLOGICAL.
On August 14th, Gelonhui reported that YuanSong Biotechnology is a joint venture of Jiangsu Bioperfectus Technologies Co., Ltd. and the company holds 9.0561% of its shares. Due to its own business development needs, YuanSong Biotechnology plans to increase its registered capital by 0.238728 million yuan, of which "Yueneng Investment," "Jingyue Jiuyuan," "Xiaofeng Teng," and "YuanSong Partnership" will subscribe for part of the capital increase. Among them, the company's related party "Jingyue Jiuyuan" contributed 30 million yuan, and "YuanSong Partnership" contributed 12 million yuan. Jiangsu Bioperfectus Technologies Co., Ltd. considers the overall development plan of the company and intends to waive its priority subscription right for this capital increase. After the completion of this transaction
No Data